Cofrogliptin

CAS No. 1844874-26-5

Cofrogliptin( —— )

Catalog No. M35685 CAS No. 1844874-26-5

Cofrogliptin (HSK7653) is an orally available dipeptidyl peptidase-4 (DPP-4) inhibitor with hypoglycemic effects, which can be used to study type 2 diabetes (T2D).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 178 Get Quote
5MG 275 Get Quote
10MG 440 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cofrogliptin
  • Note
    Research use only, not for human use.
  • Brief Description
    Cofrogliptin (HSK7653) is an orally available dipeptidyl peptidase-4 (DPP-4) inhibitor with hypoglycemic effects, which can be used to study type 2 diabetes (T2D).
  • Description
    Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
  • In Vitro
    Cofrogliptin (HSK7653) (compound 2) has the DPP-4 inhibitory activity with an IC50 value of 4.18 nM.
  • In Vivo
    Cofrogliptin (HSK7653) (compound 2) (IV: 0.5 mg/kg; PO: 2 mg/kg) exhibits extremely long half-lives and low rate of reduction of drug concentration after orally administration.Cofrogliptin (compound 2) (Single, orally, 3 mg/kg, 10 mg/kg, 30 mg/kg) increases of half-lives, has high oral exposure, low i.v. clearance and hepatic microsomal clearance after intravenous dosing. Cofrogliptin (compound 2) (Single, orally, 10 mg/kg) exhibits longe inhibition time of DPP-4 and decreases HbA1c level at the doses of 3 and 10 mg/kg in ob/ob mice. Cofrogliptin (compound 2) (Single, orally, 10 mg/kg) also has a great potential of biweekly regimen for T2DM as indicated in rhesus monkeys.Animal Model:ob/ob mice Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg Administration: Single, orally, 3 mg/kg, 10 mg/kg, 30 mg/kg Result:Exhibited strong inhibition capability of plasma DPP-4 in a dose dependent manner. Animal Model:rhesus monkeys Dosage:10 mg/kg Administration:Single, orally, 10 mg/kg Result: Possessed the capability of plasma DPP-4 inhibition over 80% for at least 12 days.Remained the plasma DPP-4 inhibition rates of 76.16% and 43.41%, respectively at the end of second week and third week after administration.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    DPP
  • Recptor
    DPP-4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1844874-26-5
  • Formula Weight
    466.43
  • Molecular Formula
    C18H19F5N4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (214.39 mM; Ultrasonic )
  • SMILES
    C(F)(F)(F)[C@@H]1[C@@H](C[C@H](N)[C@H](O1)C2=C(F)C=CC(F)=C2)N3CC=4C(C3)=NN(S(C)(=O)=O)C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. International NonproprietaryNames for PharmaceuticalSubstances (INN)
molnova catalog
related products
  • NU1025

    NU1025 is a potent PARP inhibitor with IC50 of 400 nM.

  • Trelagliptin

    Trelagliptin is a highly selective, long-acting DPP-4 inhibitor. Phase 3.

  • Imigliptin dihydroch...

    A novel potent, selective, orally available DPP-4 inhibitor with IC50 of 9 nM.